Partner Rob Freedman recently spoke with Law360 following BioAge's upsized $238 million IPO and concurrent private placement to highlight the avid capital markets interest in obesity treatments.
“Obesity treatments and metabolic health solutions are receiving unprecedented attention in U.S. capital markets, reflecting a robust confidence in their potential impact,” commented Rob, who advised BioAge in its IPO and private placement.
“As new GLP-1 combination treatments and other innovative therapies gain traction, we expect this sector to play a pivotal role in revolutionizing healthcare and improving lives.”
Law360 notes that this increased interest in the obesity market signals a strong pipeline of IPOs for the wider biotech sector moving into 2025.
Read the full analysis on Law360 (subscription required).